3540 C.I. MEDICAL CO.,LTD. - Financial Results

About Information Provided on This Site

The information provided on our website 'Kabutan.com' is not intended to constitute investment solicitation or investment advisory services.
All investment decisions should be made at your own discretion and judgment.
The data on our website is provided by Tokyo Stock Exchange, Osaka Exchange, Nagoya Securities Exchange, JPX Market Innovation & Research, Japannext, and other sources.
Copyright of the Nikkei Stock Average belongs to Nikkei Inc. Stock price charts displayed on Kabutan.com are provided solely for the purpose of reviewing historical price movements of the securities.
These charts neither suggest nor guarantee future price movements of the securities and do not constitute recommendations to buy or sell.
In our financial results coverage, the term 'Surprise Results' identifies securities that demonstrate a significant degree of surprise in their earnings announcements.
This significance is quantitatively assessed based on multiple factors, including: the nature of the announcement (full-year or quarterly results); types of revisions (earnings or dividend forecasts); and numerical analysis comparing the announced results with both the company's previous forecasts and historical performance.
The 'Surprise Ranking' presents these results in order of their calculated surprise factor. Please note that neither these results nor rankings are intended to suggest or guarantee future performance of the listed securities, nor should they be construed as recommendations to buy or sell.

3540

TSE Standard

C.I. MEDICAL CO.,LTD.

883

JPY

+39

(+4.62%)

May 7, 3:30 pm JST

6.17

USD

May 7, 2:30 am EDT

Result

PTS

outside of trading hours

ー

Summary Chart Historical News Financial Result

Current Period Guidance

Annual

Result

Guidance History

Growth Rate

Profitability

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Dec, 2021	41,205	4,523	4,605	2,820	56.4	5.64	Feb 10, 2022	J-GAAP
Dec, 2022	42,891	3,990	3,889	2,521	50.4	5.04	Feb 14, 2023	J-GAAP
Dec, 2023	45,628	2,989	3,295	2,082	41.7	5.04	Feb 13, 2024	J-GAAP
Dec, 2024	67,493	2,493	2,621	6,266	125.3	12.53	Feb 12, 2025	J-GAAP
Dec, 2025 Guidance	95,000	4,135	4,268	3,128	62.6	－	Feb 12, 2025	J-GAAP
YoY	+40.8%	+65.9%	+62.8%	-50.1%	-50.1%

Revision Direction	Revision Date	Revenue	Operating Profit	Ordinary Profit	Net Profit	Revised Dividend	Accounting Standards
Dec, 2020	Feb 13, 2020	32,001	2,328	2,290	1,580	－	J-GAAP
-	Oct 20, 2020	33,900	3,300	3,400	2,200	－	J-GAAP
-	Jan 26, 2021	37,393	4,669	4,741	2,882	－	J-GAAP
- Results	Feb 12, 2021	37,393	4,702	4,773	2,920	11.68	J-GAAP
Dec, 2021	Feb 12, 2021	Available in future release
Results	Feb 10, 2022
Dec, 2022	Feb 10, 2022
Results	Feb 14, 2023
Dec, 2023	Feb 14, 2023
Results	Feb 13, 2024
Dec, 2024	Feb 13, 2024
	Nov 7, 2024
Results	Feb 12, 2025
Dec, 2025	Feb 12, 2025	95,000	4,135	4,268	3,128	－	J-GAAP

Fiscal Year	Revenue	YoY	Operating Profit	YoY	Ordinary Profit	YoY	Adj. EPS	YoY
Dec, 2012	10,947	－	Available in future release
Dec, 2013	13,236	+20.9
Dec, 2014	15,926	+20.3
Dec, 2015	18,145	+13.9
Dec, 2016	20,334	+12.1
Dec, 2017	22,830	+12.3
Dec, 2018	25,806	+13.0
Dec, 2019	28,763	+11.5
Dec, 2020	37,393	+30.0
Dec, 2021	41,205	+10.2
Dec, 2022	42,891	+4.1
Dec, 2023	45,628	+6.4
Dec, 2024	67,493	+47.9
Dec, 2025 Guidance	95,000	+40.8	4,135	+65.9	4,268	+62.8	62.6	-50.0

Fiscal Year	Revenue	Operating Profit	Operating Profit Margin	ROE	ROA	Total Asset Turnover Ratio	Adj. EPS
Dec, 2023	45,628	2,989	6.55	10.88	5.81	1.27	41.7
Dec, 2024	67,493	2,493	3.69	27.15	11.97	1.29	125.3
Dec, 2025 Guidance	95,000	4,135	4.35	11.99	4.95	1.50	62.6

All-Time High

	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS
Record	67,493	4,702	4,773	6,266	125.3
Fiscal Year	Dec, 2024	Dec, 2020	Dec, 2020	Dec, 2024	Dec, 2024

First Half

Result

Guidance History

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Jan - Jun, 2022	20,963	2,325	2,333	1,528	30.6	0	Aug 9, 2022	J-GAAP
Jan - Jun, 2023	22,197	1,768	1,953	1,226	24.5	0	Aug 8, 2023	J-GAAP
Jan - Jun, 2024	24,316	983	971	577	11.6	0	Aug 13, 2024	J-GAAP
Jan - Jun, 2025 Guidance	46,114	1,842	1,917	1,598	32.0	－	Feb 12, 2025	J-GAAP
YoY	+89.6%	+87.4%	+97.4%	+176.9%	+176.7%

Revision Direction	Revision Date	Revenue	Operating Profit	Ordinary Profit	Net Profit	Revised Dividend	Accounting Standards
Jun, 2022	Feb 10, 2022	ー	ー	ー	ー	－	J-GAAP
- - - - - Results	Aug 9, 2022	20,963	2,325	2,333	1,528	0	J-GAAP
Jun, 2023	Feb 14, 2023	Available in future release
Results	Aug 8, 2023
Jun, 2024	Feb 13, 2024
Results	Aug 13, 2024
Jun, 2025	Feb 12, 2025	46,114	1,842	1,917	1,598	－	J-GAAP

Cash Flow

Annual

Fiscal Year	Operating Profit	Fee Cash Flow	Operating Cash Flow	Investing Cash Flow	Financial Cash Flow	Cash & Equivalents	Cash Ratio	Accounting Standards
Dec, 2022	3,990	-8,640	1,409	-10,049	6,710	1,731	5.73	J-GAAP
Dec, 2023	2,989	-9,951	-156	-9,795	9,825	1,698	4.09	J-GAAP
Dec, 2024	2,493	2,048	6,153	-4,105	376	4,124	6.53	J-GAAP

Actual Performance and Financial Trends

Historical Performance

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Dec, 2022	42,891	3,990	3,889	2,521	50.4	5.04	Feb 14, 2023	J-GAAP
Dec, 2023	45,628	2,989	3,295	2,082	41.7	5.04	Feb 13, 2024	J-GAAP
Dec, 2024	67,493	2,493	2,621	6,266	125.3	12.53	Feb 12, 2025	J-GAAP
YoY	+47.9%	-16.6%	-20.5%	+201.0%	+200.9%

Quarterly Results

Result

Growth Rate

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Operating Profit Margin	Announce	Accounting Standards
Jan - Mar, 2023	10,999	786	851	521	10.4	7.1	May 9, 2023	J-GAAP
Apr - Jun, 2023	11,198	982	1,102	705	14.1	8.8	Aug 8, 2023	J-GAAP
Jul - Sep, 2023	11,451	780	799	513	10.3	6.8	Nov 13, 2023	J-GAAP
Oct - Dec, 2023	11,980	441	543	343	6.9	3.7	Feb 13, 2024	J-GAAP
Jan - Mar, 2024	11,946	407	407	247	5.0	3.4	May 14, 2024	J-GAAP
Apr - Jun, 2024	12,370	576	564	330	6.6	4.7	Aug 13, 2024	J-GAAP
Jul - Sep, 2024	20,932	125	314	4,760	95.2	0.6	Nov 12, 2024	J-GAAP
Oct - Dec, 2024	22,245	1,385	1,336	929	18.6	6.2	Feb 12, 2025	J-GAAP
YoY	+85.7%	+214.1%	+146.0%	+170.8%	+170.8%

Fiscal Year	Revenue	YoY	Operating Profit	YoY	Ordinary Profit	YoY	Adj. EPS	YoY
Jan - Mar, 2020	8,280	+22.2	Available in future release
Apr - Jun, 2020	8,694	+24.3
Jul - Sep, 2020	9,519	+15.6
Oct - Dec, 2020	10,900	+61.3
Jan - Mar, 2021	10,480	+26.6
Apr - Jun, 2021	9,934	+14.3
Jul - Sep, 2021	10,186	+7.0
Oct - Dec, 2021	10,605	-2.7
Jan - Mar, 2022	10,417	-0.6
Apr - Jun, 2022	10,546	+6.2
Jul - Sep, 2022	10,505	+3.1
Oct - Dec, 2022	11,423	+7.7
Jan - Mar, 2023	10,999	+5.6
Apr - Jun, 2023	11,198	+6.2
Jul - Sep, 2023	11,451	+9.0
Oct - Dec, 2023	11,980	+4.9
Jan - Mar, 2024	11,946	+8.6
Apr - Jun, 2024	12,370	+10.5
Jul - Sep, 2024	20,932	+82.8
Oct - Dec, 2024	22,245	+85.7	1,385	+214.1	1,336	+146.0	18.6	+169.6

All-Time High Quarterly Results

	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS
Record	22,245	1,633	1,659	4,760	95.2
Fiscal Year	Dec, 2024	Dec, 2020	Dec, 2020	Sep, 2024	Sep, 2024

Key Balance Sheet Figures

Fiscal Year	BPS	Equity Ratio	Total Asset	Equity	Retained Earnings	Interest-Bearing Debt Ratio	Announce	Accounting Standards
Dec, 2022	1,821.65	60.3	30,186	18,216	18,249	0.39	Feb 14, 2023	J-GAAP
Dec, 2023	2,005.86	48.3	41,506	20,058	20,079	0.86	Feb 13, 2024	J-GAAP
Dec, 2024	521.91	41.3	63,166	26,095	26,094	0.81	Feb 12, 2025	J-GAAP

C.I. MEDICAL CO.,LTD.(3540) Financial Results